Endo Agrees To $90 Million In Milestone Payments For Opana ER
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm also commits to a tiered royalty schedule to resolve dispute with development partner Penwest.
You may also be interested in...
Endo Ketoprofen Patch Fails Two Phase III Studies; Firm Revises 2007 Guidance
Endo awaits results from another Phase III efficacy study expected by Aug. 1 before it makes a go/no go decision on the product.
Endo Ketoprofen Patch Fails Two Phase III Studies; Firm Revises 2007 Guidance
Endo awaits results from another Phase III efficacy study expected by Aug. 1 before it makes a go/no go decision on the product.
Opana Uptake Slower Than Anticipated, But Script Growth Is On The Rise
Scripts for Endo's oral oxymorphone reached 1,137 the week of Sept. 29, according to IMS weekly trend data.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: